Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 14/20 | 0.72 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488246 | 0.96 | FGFR2 (0.69) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4482174 | 0.93 | FGFR2 (0.84) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4461146 | 0.92 | FGFR2 (0.76) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4468108 | 0.91 | FGFR2 (0.72) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4470009 | 0.91 | FGFR2 (0.85) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4476123 | 0.90 | FGFR2 (0.78) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4471412 | 0.89 | FGFR2 (0.70) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4488788 | 0.88 | FGFR2 (0.70) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4471863 | 0.88 | FGFR2 (0.70) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4464922 | 0.87 | FGFR2 (0.82) | FGFR2KDRPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | claimed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1447405-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | FGFR1, FGFR2, FGFR3 | FGFR2 2/4885KDR 211/4885PDGFRB 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.